We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Alliance for Molecular Bladder Cancer Detection

By HospiMedica staff writers
Posted on 02 Jan 2003
An agreement to sublicense exclusive worldwide diagnostic rights to develop and commercialize an immunohistochemistry test to detect the presence of the CD52 antigen in lymph nodes has been announced by Ilex Oncology, Inc. More...
(San Antonio, TX, USA). The licensee is Ventana Medical Systems (Tucson, AZ, USA). The agreement is intended to aid the rapid commercialization of Ilex's cancer drug.

"A standardized test will accelerate the routine screening of the CD52 antigen, which, according to recent findings, appears to be associated with several types of cancer, including lymphomas, in addition to B-cell chronic lymphocytic leukemia (B-CLL). It will also serve as a valuable tool enabling Ilex clinicians to pinpoint cancers in which Campath may play a key therapeutic role.”

Campath (alemtuzumab) is used for the treatment of patients with B-CLL who have been treated with alkylating agents and failed fludarabine therapy. The drug works by targeting the CD52 antigen, resulting in the removal of malignant lymphocytes from the blood, lymph nodes, bone marrow, and other affected organs. Campath is the product of Ilex. Recently, Ilex acquired exclusive commercial rights to CD52 antigen testing from BTG International Limited.





Related Links:
Ilex
Ventana

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Aspiration System
VACUSAFE
New
Multi-Chamber Washer-Disinfector
WD 390
New
Repetitive Pipette
VWR® Stepper Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The device contains specific antibodies that capture the primary biomarker of pancreatic cancer. The binding of these antibodies alters the distribution of electrical charges on the electrode surface. The sensor then translates this variation into a measurable capacitance signal (photo courtesy of Gabriella Soares / IFSC-USP)

Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection

Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.